Timothy Wilkin
Timothy Wilkin, Weill Cornell Medical College, New York
A protease inhibitor, currently known as TMC114 has been tested in the POWER II study among some 300 patients who had failed multiple regimens. Six month data have now yielded dose and toxicity findings and some preliminary recommendations for therapeutic use.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.